Följ
Jan Eriksson
Jan Eriksson
Professor of Clinical Diabetes Research, Uppsala University
Verifierad e-postadress på medsci.uu.se
Titel
Citeras av
Citeras av
År
Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes
BO Ahrén, E Simonsson, H Larsson, M Landin-Olsson, H Torgeirsson, ...
Diabetes care 25 (5), 869-875, 2002
5492002
Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes …
B Littorin, P Blom, A Schölin, HJ Arnqvist, G Blohme, J Bolinder, ...
Diabetologia 49 (12), 2847-2852, 2006
3672006
Fat cell enlargement is an independent marker of insulin resistance and ‘hyperleptinaemia’
M Lundgren, M Svensson, S Lindmark, F Renström, T Ruge, JW Eriksson
Diabetologia 50 (3), 625-633, 2007
3572007
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs …
KI Birkeland, ME Jørgensen, B Carstensen, F Persson, HL Gulseth, ...
The lancet Diabetes & endocrinology 5 (9), 709-717, 2017
3322017
Regional differences of insulin action in adipose tissue: insights from in vivo and in vitro studies
F Giorgino, L Laviola, JW Eriksson
Acta Physiologica Scandinavica 183 (1), 13-30, 2005
3262005
The incidence of type I diabetes has not increased but shifted to a younger age at diagnosis in the 0–34 years group in Sweden 1983 to 1998
A Pundziute-Lyckå, G Dahlquist, L Nyström, H Arnqvist, E Björk, G Blohme, ...
Diabetologia 45 (6), 783-791, 2002
2792002
Early glycemic control, age at onset, and development of microvascular complications in childhood-onset type 1 diabetes: a population-based study in northern Sweden
M Svensson, JW Eriksson, G Dahlquist
Diabetes care 27 (4), 955-962, 2004
2722004
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised …
P Dandona, C Mathieu, M Phillip, L Hansen, SC Griffen, D Tschöpe, ...
The lancet Diabetes & endocrinology 5 (11), 864-876, 2017
2612017
The risk of venous thromboembolism is markedly elevated in patients with diabetes
V Petrauskiene, M Falk, I Waernbaum, M Norberg, JW Eriksson
Diabetologia 48 (5), 1017-1021, 2005
2492005
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
JW Eriksson, P Lundkvist, PA Jansson, L Johansson, M Kvarnström, ...
Diabetologia 61 (9), 1923-1934, 2018
2432018
Dexamethasone impairs insulin signalling and glucose transport by depletion of insulin receptor substrate-1, phosphatidylinositol 3-kinase and protein kinase B in primary …
J Burén, HX Liu, J Jensen, JW Eriksson
European journal of endocrinology 146 (3), 419-429, 2002
2302002
Glucocorticoids down-regulate glucose uptake capacity and insulin-signaling proteins in omental but not subcutaneous human adipocytes
M Lundgren, J Burén, T Ruge, T Myrnas, JW Eriksson
The Journal of Clinical Endocrinology & Metabolism 89 (6), 2989-2997, 2004
2222004
The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS)
M Henricsson, L Nyström, G Blohme, JAN Ostman, C Kullberg, ...
Diabetes care 26 (2), 349-354, 2003
2202003
Postprandial hypertriglyceridemia and insulin resistance in normoglycemic first-degree relatives of patients with type 2 diabetes
M Axelsen, U Smith, JW Eriksson, MR Taskinen, PA Jansson
Annals of internal medicine 131 (1), 27-31, 1999
2181999
Metabolic stress in insulin’s target cells leads to ROS accumulation–a hypothetical common pathway causing insulin resistance
JW Eriksson
FEBS letters 581 (19), 3734-3742, 2007
2122007
Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl …
F Persson, T Nyström, ME Jørgensen, B Carstensen, HL Gulseth, ...
Diabetes, Obesity and Metabolism 20 (2), 344-351, 2018
1882018
Low cellular IRS 1 gene and protein expression predict insulin resistance and NIDDM
E CARVALHO, PERA JANSSON, M AXELSEN, JW Eriksson, X HUANG, ...
The FASEB Journal 13 (15), 2173-2178, 1999
1871999
Fatty acid profile of the erythrocyte membrane preceding development of Type 2 diabetes mellitus
B Krachler, M Norberg, JW Eriksson, G Hallmans, I Johansson, B Vessby, ...
Nutrition, Metabolism and Cardiovascular Diseases 18 (7), 503-510, 2008
1742008
Gender differences and temporal variation in the incidence of type 1 diabetes: results of 8012 cases in the nationwide Diabetes Incidence Study in Sweden 1983–2002
J Östman, G Lönnberg, HJ Arnqvist, G Blohme, J Bolinder, AE Schnell, ...
Journal of internal medicine 263 (4), 386-394, 2008
1722008
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study
P Dandona, C Mathieu, M Phillip, L Hansen, D Tschöpe, F Thorén, J Xu, ...
Diabetes Care 41 (12), 2552-2559, 2018
1712018
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20